Table 6.
Number of children and adolescents >30 kg at risk of subcutaneous injection (STMDmax and STMDmin) or periosteal or bone injection (STBDmax and STBDmin)
| EAI | Needle length mm |
STMDmin | STMDmax | STBDmin | STBDmax |
|---|---|---|---|---|---|
| Epipen® 0.3 mg Auvi-Q® 0.3 mg |
|||||
| STBDmax | 15.2 | – | – | – | 3 |
| STMDmax | 13.2 | – | 9 | – | – |
| Jext® 0.3 mg | |||||
| STBDmax | 15.7 | – | – | – | 3 |
| STMDmax | 13.7 | – | 9 | – | – |
| Emerade® 0.3 and 0.5 mg | |||||
| STBDmin | 23.0 | – | – | 0 | – |
| STMDmin | 21.0 | 2 | – | – | – |
Number of children at risk of getting a subcutaneous injection (STMDmax and STMDmin) or injection into the periosteum or bone (STBDmax and STBDmin) for the different EAIs. The data are in percentages. For estimation of the penetration of the needle into the muscle, STMD, the needle length has been reduced by 2 mm. i.e., the length of the needle’s orifice. The thickness of the endomysium has been neglected